Indian Journal of Medical Specialities

REVIEW ARTICLE
Year
: 2019  |  Volume : 10  |  Issue : 2  |  Page : 61--65

Therapeutic benefits of lenalidomide in hematological malignancies


Mohammed Shafi Abdulsalam, Durai Mavalavan Vasudevan Manimoliyan 
 Department of Medical Oncology, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India

Correspondence Address:
Dr. Mohammed Shafi Abdulsalam
Dr. Rela Institute and Medical Centre, Chennai - 600 044, Tamil Nadu
India

Lenalidomide is an immunomodulatory agent, which has action against most of the hematological malignancies. Apart from its immunomodulation, it has other properties such as antiproliferation and antiangiogenesis. It is not only effective in myelodysplastic syndromes and myeloma, recent studies show its effective action on newly diagnosed and relapsed/refractory lymphomas as well. Addition of lenalidomide to standard therapy is associated with lesser central nervous system relapse in diffuse large B-cell lymphomas. Lenalidomide shows promising results in Hodgkin's lymphomas and leukemias (acute myeloid leukemia and chronic lymphocytic leukemia). Dose escalation may be an option in nonresponders with caution in side effects.


How to cite this article:
Abdulsalam MS, Manimoliyan DM. Therapeutic benefits of lenalidomide in hematological malignancies.Indian J Med Spec 2019;10:61-65


How to cite this URL:
Abdulsalam MS, Manimoliyan DM. Therapeutic benefits of lenalidomide in hematological malignancies. Indian J Med Spec [serial online] 2019 [cited 2020 Aug 5 ];10:61-65
Available from: http://www.ijms.in/article.asp?issn=0976-2884;year=2019;volume=10;issue=2;spage=61;epage=65;aulast=Abdulsalam;type=0